Abstract: A method of determining if a cancer patient is susceptible to survival prolongation if treatment is augmented with a clusterin-inhibiting pharmaceutical is provided. The method involves measurement of various patient data and a systematic approach to the analysis. A computer-aided system is also provided.
Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
May 14, 2012
Date of Patent:
March 24, 2015
Assignee:
Oncogenex Technologies Inc.
Inventors:
Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
Abstract: A room temperature stable and minimal aggregate liquid formulation comprises an oligonucleotide comprising Seq ID No. 1: or comprising a variant oligonucleotide in which no more than 3 non-sequential bases are different from Seq. ID NO. 1 and an aqueous carrier comprising a aggregation-preventing compound selected from the group consisting of mono and disaccharides and/or sugar alcohols.
Type:
Grant
Filed:
July 13, 2009
Date of Patent:
February 26, 2013
Assignee:
Oncogenex Technologies Inc.
Inventors:
Thomas K. Hayes, Nicole D. Krilla, Lori Nixon